Search Immortality Topics:

Page 112


Category Archives: Uncategorized

Anatomy of a Lie: How Iran Covered Up the Downing of an Airliner – The New York Times

When the Revolutionary Guards officer spotted what he thought was an unidentified aircraft near Tehrans international airport, he had seconds to decide whether to pull the trigger.

Iran had just fired a barrage of ballistic missiles at American forces, the country was on high alert for an American counterattack, and the Iranian military was warning of incoming cruise missiles.

The officer tried to reach the command center for authorization to shoot but couldnt get through. So he fired an antiaircraft missile. Then another.

The plane, which turned out to be a Ukrainian jetliner with 176 people on board, crashed and exploded in a ball of fire.

Within minutes, the top commanders of Irans Revolutionary Guards realized what they had done. And at that moment, they began to cover it up.

For days, they refused to tell even President Hassan Rouhani, whose government was publicly denying that the plane had been shot down. When they finally told him, he gave them an ultimatum: come clean or he would resign.

Only then, 72 hours after the plane crashed, did Irans supreme leader, Ayatollah Ali Khamenei, step in and order the government to acknowledge its fatal mistake.

The New York Times pieced together a chronology of those three days by interviewing Iranian diplomats, current and former government officials, ranking members of the Revolutionary Guards and people close to the supreme leaders inner circle and by examining official public statements and state media reports.

The reporting exposes the governments behind-the-scenes debate over covering up Irans responsibility for the crash while shocked Iranians, grieving relatives and countries with citizens aboard the plane waited for the truth.

The new details also demonstrate the outsize power of the Islamic Revolutionary Guards Corps, which effectively sidelined the elected government in a moment of national crisis, and could deepen what many Iranians already see as a crisis of legitimacy for the Guards and the government.

The bitter divisions in Irans government persist and are bound to affect the investigation into the crash, negotiations over compensation and the unresolved debate over accountability.

Around midnight on Jan. 7, as Iran was preparing to launch a ballistic-missile attack on American military posts in Iraq, senior members of the Islamic Revolutionary Guards Corps deployed mobile antiaircraft defense units around a sensitive military area near Tehrans Imam Khomeini Airport.

Iran was about to retaliate for the American drone strike that had killed Irans top military commander, Gen. Qassim Suleimani, in Baghdad five days earlier, and the military was bracing for an American counterstrike. The armed forces were on at war status, the highest alert level.

But in a tragic miscalculation, the government continued to allow civilian commercial flights to land and take off from the Tehran airport.

Gen. Amir Ali Hajizadeh, commander of the Guards Aerospace Force, said later that his units had asked officials in Tehran to close Irans airspace and ground all flights, to no avail.

Iranian officials feared that shutting down the airport would create mass panic that war with the United States was imminent, members of the Guards and other officials told The Times. They also hoped that the presence of passenger jets could act as a deterrent against an American attack on the airport or the nearby military base, effectively turning planeloads of unsuspecting travelers into human shields.

After Irans missile attack began, the central air defense command issued an alert that American warplanes had taken off from the United Arab Emirates and that cruise missiles were headed toward Iran.

The officer on the missile launcher near the airport heard the warnings but did not hear a later message that the cruise missile alert was a false alarm.

The warning about American warplanes may have also been wrong. United States military officials have said that no American planes were in or near Iranian airspace that night.

When the officer spotted the Ukrainian jet, he sought permission to fire. But he was unable to communicate with his commanders because the network had been disrupted or jammed, General Hajizadeh said later.

The officer, who has not been publicly identified, fired two missiles, less than 30 seconds apart.

General Hajizadeh, who was in western Iran supervising the attack on the Americans, received a phone call with the news.

I called the officials and told them this has happened and its highly possible we hit our own plane, he said later in a televised statement.

By the time General Hajizadeh arrived in Tehran, he had informed Irans top three military commanders: Maj. Gen. Abdolrahim Mousavi, the armys commander in chief, who is also the chief of the central air defense command; Maj. Gen. Mohammad Bagheri, chief of staff of the Armed Forces; and Maj. Gen. Hossein Salami, commander in chief of the Revolutionary Guards.

The Revolutionary Guards, an elite force charged with defending Irans clerical rule at home and abroad, is separate from the regular army and answers only to the supreme leader. At this point, the leaders of both militaries knew the truth.

General Hajizadeh advised the generals not to tell the rank-and-file air defense units for fear that it could hamper their ability to react quickly if the United States did attack.

It was for the benefit of our national security because then our air defense system would be compromised, Mr. Hajizadeh said in an interview with Iranian news media this week. The ranks would be suspicious of everything.

The military leaders created a secret investigative committee drawn from the Guards aerospace forces, from the armys air defense, and from intelligence and cyberexperts. The committee and the officers involved in the shooting were sequestered and ordered not to speak to anyone.

The committee examined data from the airport, the flight path, radar networks, and alerts and messages from the missile operator and central command. Witnesses the officer who had pulled the trigger, his supervisors and everyone involved were interrogated for hours.

The group also investigated the possibility that the United States or Israel may have hacked Irans defense system or jammed the airwaves.

By Wednesday night, the committee had concluded that the plane was shot down because of human error.

We were not confident about what happened until Wednesday around sunset, General Salami, the commander in chief of the Guards, said later in a televised address to the Parliament. Our investigative team concluded then that the plane crashed because of human errors.

Ayatollah Khamenei was informed. But they still did not inform the president, other elected officials or the public.

Senior commanders discussed keeping the shooting secret until the planes black boxes the flight data and cockpit voice recorders were examined and formal aviation investigations completed, according to members of the Guards, diplomats and officials with knowledge of the deliberations. That process could take months, they argued, and it would buy time to manage the domestic and international fallout that would ensue when the truth came out.

The government had violently crushed an anti-government uprising in November. But the American killing of General Suleimani, followed by the strikes against the United States, had turned public opinion around. Iranians were galvanized in a moment of national unity.

The authorities feared that admitting to shooting down the passenger plane would undercut that momentum and prompt a new wave of anti-government protests.

They advocated covering it up because they thought the country couldnt handle more crisis, said a ranking member of the Guards who, like others interviewed for this article, spoke on condition of anonymity to discuss internal deliberations. At the end, safeguarding the Islamic Republic is our ultimate goal, at any cost.

That evening, the spokesman for the Joint Armed Forces, Brig. Gen. Abolfazl Shekarchi, told Iranian news media that suggestions that missiles struck the plane were an absolute lie.

On Thursday, as Ukrainian investigators began to arrive in Tehran, Western officials were saying publicly that they had evidence that Iran had accidentally shot down the plane.

A chorus of senior Iranian officials from the director of civil aviation to the chief government spokesman issued statement after statement rejecting the allegations, their claims amplified on state media.

The suggestion that Iran would shoot down a passenger plane was a Western plot, they said, psychological warfare aimed at weakening Iran just as it had exercised its military muscle against the United States.

But in private, government officials were alarmed and questioning whether there was any truth to the Western claims. Mr. Rouhani, a seasoned military strategist himself, and his foreign minister, Javad Zarif, deflected phone calls from world leaders and foreign ministers seeking answers. Ignorant of what their own military had done, they had none to give.

Domestically, public pressure was building for the government to address the allegations.

Among the planes passengers were some of Irans best and brightest. They included prominent scientists and physicians, dozens of Irans top young scholars and graduates of elite universities, and six gold and silver medal winners of international physics and math Olympiads.

There were two newlywed couples who had traveled from Canada to Tehran for their weddings just days earlier. There were families and young children.

Their relatives demanded answers. Iranian social media began to explode with emotional commentary, some accusing Iran of murdering its own citizens and others calling such allegations treason.

Persian-language satellite channels operating from abroad, the main source of news for most Iranians, broadcast blanket coverage of the crash, including reports from Western governments that Iran had shot down the plane.

Mr. Rouhani tried several times to call military commanders, officials said, but they did not return his calls. Members of his government called their contacts in the military and were told the allegations were false. Irans civil aviation agency called military officials with similar results.

Thursday was frantic, Ali Rabiei, the government spokesman, said later in a news conference. The government made back-to-back phone calls and contacted the armed forces asking what happened, and the answer to all the questions was that no missile had been fired.

On Friday morning, Mr. Rabiei issued a statement saying the allegation that Iran had shot down the plane was a big lie.

Several hours later, the nations top military commanders called a private meeting and told Mr. Rouhani the truth.

Mr. Rouhani was livid, according to officials close to him. He demanded that Iran immediately announce that it had made a tragic mistake and accept the consequences.

The military officials pushed back, arguing that the fallout could destabilize the country.

Mr. Rouhani threatened to resign.

Canada, which had the most foreign citizens on board the plane, and the United States, which as Boeings home country was invited to investigate the crash, would eventually reveal their evidence, Mr. Rouhani said. The damage to Irans reputation and the public trust in the government would create an enormous crisis at a time when Iran could not bear more pressure.

As the standoff escalated, a member of Ayatollah Khameneis inner circle who was in the meeting informed the supreme leader. The ayatollah sent a message back to the group, ordering the government to prepare a public statement acknowledging what had happened.

Mr. Rouhani briefed a few senior members of his government. They were rattled.

Mr. Rabiei, the government spokesman who had issued a denial just that morning, broke down. Abbas Abdi, a prominent critic of Irans clerical establishment, said that when he spoke to Mr. Rabiei that evening, Mr. Rabiei was distraught and crying.

Everything is a lie, Mr. Rabiei said, according to Mr. Abdi. The whole thing is a lie. What should I do? My honor is gone.

Mr. Abdi said the governments actions had gone far beyond just a lie.

There was a systematic cover-up at the highest levels that makes it impossible to get out of this crisis, he said.

Irans National Security Council held an emergency meeting and drafted two statements, the first to be issued by the Joint Armed Forces followed by a second one from Mr. Rouhani.

As they debated the wording, some suggested claiming that the United States or Israel may have contributed to the accident by jamming Irans radars or hacking its communications networks.

But the military commanders opposed it. General Hajizadeh said the shame of human error paled compared with admitting his air defense system was vulnerable to hacking by the enemy.

Irans Civil Aviation Agency later said that it had found no evidence of jamming or hacking.

At 7 a.m., the military released a statement admitting that Iran had shot down the plane because of human error.

The bombshell revelation has not ended the division within the government. The Revolutionary Guards want to pin the blame on those involved in firing the missiles and be done with it, officials said. The missile operator and up to 10 others have been arrested but officials have not identified them or said whether they had been charged.

Mr. Rouhani has demanded a broader accounting, including an investigation of the entire chain of command. The Guards accepting responsibility, he said, is the first step and needs to be completed with other steps. His spokesman and lawmakers have demanded to know why Mr. Rouhani was not immediately informed.

Mr. Rouhani touched on that concern when he put out his statement an hour and 15 minutes later. The first line said that he had found out about the investigative committees conclusion about cause of the crash a few hours ago.

It was a stunning admission, an acknowledgment that even the nations highest elected official had been shut out from the truth, and that as Iranians, and the world, turned to the government for answers, it had peddled lies.

What we thought was news was a lie. What we thought was a lie was news, said Hesamedin Ashna, Mr. Rouhanis top adviser, on Twitter. Why? Why? Beware of cover-ups and military rule.

See the original post here:
Anatomy of a Lie: How Iran Covered Up the Downing of an Airliner - The New York Times

Posted in Anatomy, Uncategorized | Comments Off on Anatomy of a Lie: How Iran Covered Up the Downing of an Airliner – The New York Times

Regenerative medicine consultation service – Mayo Clinic …

At Mayo Clinic, an integrated team, including stem cell biologists, bioengineers, doctors and scientists, work together and study regenerative medicine. The goal of the team is to treat diseases using novel therapies, such as stem cell therapy and bioengineering. Doctors in transplant medicine and transplant surgery have pioneered the study of regenerative medicine during the past five decades, and doctors continue to study new innovations in transplant medicine and surgery.

In stem cell therapy, or regenerative medicine, researchers study how stem cells may be used to replace, repair, reprogram or renew your diseased cells. Stem cells are able to grow and develop into many different types of cells in your body. Stem cell therapy may use adult cells that have been genetically reprogrammed in the laboratory (induced pluripotent stem cells), your own adult stem cells that have been reprogrammed or cells developed from an embryo (embryonic stem cells).

Researchers also study and test how reprogrammed stem cells may be turned into specialized cells that can repair or regenerate cells in your heart, blood, nerves and other parts of your body. These stem cells have the potential to treat many conditions. Stem cells also may be studied to understand how other conditions occur, to develop and test new medications, and for other research.

Researchers across Mayo Clinic, with coordination through the Center for Regenerative Medicine, are discovering, translating and applying stem cell therapy as a potential treatment for cardiovascular diseases, diabetes, degenerative joint conditions, brain and nervous system (neurological) conditions, such as Parkinson's disease, and many other conditions. For example, researchers are studying the possibility of using stem cell therapy to repair or regenerate injured heart tissue to treat many types of cardiovascular diseases, from adult acquired disorders to congenital diseases. Read about regenerative medicine research for hypoplastic left heart syndrome.

Cardiovascular diseases, neurological conditions and diabetes have been extensively studied in stem cell therapy research. They've been studied because the stem cells affected in these conditions have been the same cell types that have been generated in the laboratory from various types of stem cells. Thus, translating stem cell therapy to a potential treatment for people with these conditions may be a realistic goal for the future of transplant medicine and surgery.

Researchers conduct ongoing studies in stem cell therapy. However, research and development of stem cell therapy is unpredictable and depends on many factors, including regulatory guidelines, funding sources and recent successes in stem cell therapy. Mayo Clinic researchers aim to expand research and development of stem cell therapy in the future, while keeping the safety of patients as their primary concern.

Mayo Clinic offers stem cell transplant (bone marrow transplant) for people who've had leukemia, lymphoma or other conditions that have been treated with chemotherapy.

Mayo Clinic currently offers a specialty consult service for regenerative medicine within the Transplant Center, the first consult service established in the United States to provide guidance for patients and families regarding stem cell-based protocols. This consult service provides medical evaluations for people with many conditions who have questions about the potential use of stem cell therapy. The staff provides guidance to determine whether stem cell clinical trials are appropriate for these individuals. Regenerative medicine staff may be consulted if a doctor or patient has asked about the potential use of stem cell therapies for many conditions, including degenerative or congenital diseases of the heart, liver, pancreas or lungs.

People sometimes have misconceptions about the use and applications of stem cell therapies. This consult service provides people with educational guidance and appropriate referrals to research studies and clinical trials in stem cell therapies for the heart, liver, pancreas and other organs. Also, the consult service supports ongoing regenerative medicine research activities within Mayo Clinic, from basic science to clinical protocols.

Read more about stem cells.

Share your Mayo Clinic transplant experience with others using social media.

Read this article:
Regenerative medicine consultation service - Mayo Clinic ...

Posted in Uncategorized | Comments Off on Regenerative medicine consultation service – Mayo Clinic …

Regenerative Medicine – WOMEN IN MEDICINE LTD

This site uses cookies to improve performance. If your browser does not accept cookies, you cannot view this site.

There are many reasons why a cookie could not be set correctly. Below are the most common reasons:

This site uses cookies to improve performance by remembering that you are logged in when you go from page to page. To provide access without cookies would require the site to create a new session for every page you visit, which slows the system down to an unacceptable level.

This site stores nothing other than an automatically generated session ID in the cookie; no other information is captured.

In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a website to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it.

Link:
Regenerative Medicine - WOMEN IN MEDICINE LTD

Posted in Uncategorized | Comments Off on Regenerative Medicine – WOMEN IN MEDICINE LTD

Organogenesis.com – Science – Regenerative Medicine

Regenerative medicine is a multidisciplinary field involving biology, medicine and engineering. It combines the physical nature of a product with living cells.

"Tissue Regeneration," "Tissue Engineering" and "Regenerative Medicine" are related terms and are sometimes used interchangeably.

Where does regenerative medicine fit into modern medical practice? Current traditional approaches to treat medical diseases include:

These methods are all considered essential, but have their limitations. For example, drugs have unwanted side effects, prosthetics are not biologically active and do not integrate or remodel into the body, surgery is invasive, and organ transplantation is limited by donor availability and toxic immunosuppressive cocktails.

Regenerative medicine is an emerging approach in modern medicine as it delivers living tissue, stimulating the body's own natural healing process by activating the body's inherent ability to repair and regenerate. Innovative therapies are now available that aim to heal or reconstruct diseased tissue and support the regeneration of diseased or injured cells and organs.

Doctors use regenerative medicine to speed up healing and to help injuries that will not heal or repair on their own. Regenerative medicine may help heal broken bones, severe burns, chronic wounds, heart damage, nerve damage, and many other diseases.

More here:
Organogenesis.com - Science - Regenerative Medicine

Posted in Uncategorized | Comments Off on Organogenesis.com – Science – Regenerative Medicine

IRM at UPenn – Institute For Regenerative Medicine – Phila

The Institute for Regenerative Medicine is based in the Smilow Center for Translational Research and extends across UPenns campus.

The links between medicine, engineering and veterinary science differentiate Penns Institute for Regenerative Medicine from other stem cell Institutes across the country.

The IRM promotes discoveries in stem cell biology and regeneration to generate new therapies that may alleviate suffering and disease.

When our interdisciplinary research and programs bring together individuals with broad interests and diverse backgrounds, our collaborations lead to greater advances.

Stem cell research is critical to developing new skin tissues and, ultimately, changing the way we care for devastating wounds.

At Penn, we're discovering real possibilities of future treatments for cardiac disease because we have the research and clinical expertise to make it happen.

Thursday - April 21, 2016

Finding could lead to better drugs for the many asthma patients who dont respond well to current medications PHILADELPHIAAsthma is an enormous public health problem that continues to grow larger, in part because scientists dont

Read More...

Wednesday - March 23, 2016

This spring, the BioEYES program celebrates a major milestone: It will serve its 100,000th student. That means in the 14 years since BioEYES began, 100,000 elementary, middle, and high school students from Philadelphia and four

Read More...

Wednesday - February 10, 2016

A study from researchers at The Childrens Hospital of Philadelphia may add new lines to the textbook description of how cancer cells divide uncontrollably and develop into tumors. Their study, published in Nature Communications, identifies

Read More...

Follow this link:
IRM at UPenn - Institute For Regenerative Medicine - Phila

Posted in Uncategorized | Comments Off on IRM at UPenn – Institute For Regenerative Medicine – Phila

Regenerative Medicine Conferences | Europe | CPD Events …

The 5th International Conference on Tissue Engineering & Regenerative Medicine which is going to be held during September 12-14, 2016 at Berlin, Germany will bring together world-class personalities working on stem cells, tissue engineering and regenerative medicine to discuss materials-related strategies for disease remediation and tissue repair.

Tissue Regeneration

In the field of biology, regeneration is the progression of renewal, regeneration and growth that makes it possible for genomes, cells, organ regeneration to natural changes or events that cause damage or disturbance.This study is carried out as craniofacial tissue engineering, in-situtissue regeneration, adipose-derived stem cells for regenerative medicine which is also a breakthrough in cell culture technology. The study is not stopped with the regeneration of tissue where it is further carried out in relation with cell signaling, morphogenetic proteins. Most of the neurological disorders occurred accidental having a scope of recovery by replacement or repair of intervertebral discs repair, spinal fusion and many more advancements. The global market for tissue engineering and regeneration products such as scaffolds, tissueimplants, biomimetic materials reached $55.9 billion in 2010 and it is expected to reach $89.7 billion by 2016 at a compounded annual growth rate (CAGR) of 8.4%. It grows to $135 billion by 2024.

Related Conferences

5th InternationalConference on Tissue Engineering and Regenerative Medicine September 12-14, 2016 Berlin, Germany; 5th International Conference onCell and Gene Therapy May 19-21, 2016 San Antonio, USA; InternationalConference on Cancer Immunologyand ImmunotherapyJuly 28-30, 2016 Melbourne, Australia; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; Tissue Niches and Resident Stem Cells in Adult Epithelia Gordon Research Conference, Regulation of Tissue Homeostasis by Signalling in the Stem Cell Niche August 7-12, Hong Kong, China; 10 Years of IPSCs, Cell Symposia, September 25-27, 2016 Berkeley, CA, USA; World Stem Cells and Regenerative Medicine Congress May 18-20, 2016 London, UK; Notch Signaling in Development, Regeneration and Disease Gordon Research Conference, July 31-August 5, 2016 Lewiston, ME, USA

Designs for Tissue Engineering

The developing field of tissue engineering aims to regenerate damaged tissues by combining cells from the body withbioresorbablematerials, biodegradable hydrogel, biomimetic materials, nanostructures andnanomaterials, biomaterials and tissue implants which act as templates for tissue regeneration, to guide the growth of new tissue by using with the technologies. The global market for biomaterials, nanostructures and bioresorbable materials are estimated to reach $88.4 billion by 2017 from $44.0 billion in 2012 growing at a CAGR of 15%. Further the biomaterials market estimated to be worth more than 300 billion US Dollars and to be increasing 20% per year.

Related Conferences

5th International ConferenceonCell and Gene Therapy May 19-21, 2016 San Antonio, USA; International Conference on Restorative Medicine October 24-26, 2016 Chicago, USA; InternationalConference on Molecular Biology October 13-15, 2016 Dubai, UAE; 2nd International Conference on Bio-banking August 18-19, 2016 Portland, USA; ISSCR Annual Meeting 22-25 June, 2016 San Francisco, California, USA; Keystone Cardiac Development, Regeneration and Repair (Z2) April 3 7, 2016 Snowbird, Utah, USA;EMBL Hematopoietic Stem Cells: From the Embryo to the Aging Organism, June 3-5, 2016 Heidelberg, Germany; ISSCR Pluripotency: From basic science to therapeutic applications March 22-24, 2016 Kyoto, Japan

Organ Engineering

This interdisciplinary engineering has attracted much attention as a new therapeutic means that may overcome the drawbacks involved in the current artificial organs and organtransplantationthat have been also aiming at replacing lost or severely damaged tissues or organs. Tissue engineering and regenerative medicine is an exciting research area that aims at regenerative alternatives to harvested tissues for organ transplantation with soft tissues. Although significant progress has been made in thetissue engineeringfield, many challenges remain and further development in this area will require ongoing interactions and collaborations among the scientists from multiple disciplines, and in partnership with the regulatory and the funding agencies. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.

Related Conferences

International Conference on Restorative Medicine October 24-26, 2016 Chicago, USA; 5th InternationalConference on Cell and Gene Therapy May 19-21, 2016 San Antonio, USA; 5th International Conference on Regenerative Medicine September 12-14, 2016 Berlin, Germany; 2nd International Conference on Tissue preservation August 18-19, 2016 Portland, USA;Cell and Gene TherapyJanuary 25-27, 2016 Washington D.C., USA; ISSCR Stem Cell Models of Neural Degeneration and Disease February 1-3, 2016 Dresden, Germany; Craniofacial Morphogenesis and Tissue Regeneration March 12-18, 2016 California, USA; Keystone Stem Cells and Cancer (C1) March 6-10, Colorado, USA; Keystone Stem Cells and Regeneration in the Digestive Organs (X6) March 13 17 Colorado, USA

Cancer Stem Cells

The characterization of cancer stem cell is done by identifying the cell within a tumor that possesses the capacity to self-renew and to cause theheterogeneous lineagesof cancer cells that comprise the tumor. This stem cell which acts as precursor for the cancer acts as a tool against it indulging the reconstruction of cancer stem cells, implies as the therapeutic implications and challenging the gaps globally. The global stem cell market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 3.6% from 2013 through 2018. The Americas is the largest region of globalstem cellmarket, with a market share of about $2.0 billion in 2013. The region is projected to increase to nearly $3.9 billion by 2018, with a CAGR of 13.9% for the period of 2013 to 2018. Europe is the second largest segment of the global stem cell market and is expected to grow at a CAGR of 13.4% reaching about $2.4 billion by 2018 from nearly $1.4 billion in 2013.

Related Conferences

5th InternationalConference Cell and Gene Therapy May 19-21, 2016 San Antonio, USA; International Conference on Molecular Biology October 13-15, 2016 Dubai, UAE; 5th International Conference on Tissue EngineeringSeptember 12-14, 2016 Berlin, Germany; 2nd International Conference on Tissue preservationAugust 18-19, 2016 Portland, USA; Molecular and Cellular Basis of Growth and Regeneration (A3) January 10 14, 2016 Colorado, USA; Cell and Gene TherapyJanuary 25-27, 2016 Washington D.C., USA; ISSCR Stem Cell Models of Neural Degeneration and Disease March 13 17, 2016 Dresden, Germany; Craniofacial Morphogenesis and Tissue Regeneration March 12-18, 2016 California, USA; World Stem Cells Congress May 18-20, 2016 London, UK

Bone Tissue Engineering

Tissue engineering ofmusculoskeletal tissues, particularly bone and cartilage, is a rapidly advancing field. In bone, technology has centered on bone graft substitute materials and the development of biodegradable scaffolds. Recently, tissue engineering strategies have included cell and gene therapy. The availability of growth factors and the expanding knowledge base concerning the bone regeneration with modern techniques like recombinant signaling molecules, solid free form fabrication of scaffolds, synthetic cartilage, Electrochemical deposition,spinal fusionand ossification are new generated techniques for tissue-engineering applications. The worldwide market for bone and cartilage repairs strategies is estimated about $300 million. During the last 10/15 years, the scientific community witnessed and reported the appearance of several sources of stem cells with both osteo and chondrogenic potential.

Related Conferences

5th International Conference on Tissue Engineering and Regenerative Medicine September 12-14, 2016 Berlin, Germany; 3rd 2nd International Conference on Tissue preservation and Bio-banking August 18-19, 2016 Portland, USA; 5th International Conference on Cell and Gene Therapy May 19-21, 2016 San Antonio, USA; International Conference on Restorative Medicine October 24-26, 2016 Chicago, USA; 10th World Biomaterials Congress May 17-22, 2016 Quebec, Canada; 2016 TERMIS-EU Conference June 28- July1, 2016 Uppsala, Sweden; 2016 TERMIS-AP Conference Tamsui Town of New Taipei City May 23-28, 2016; 2016 TERMIS-AM Conference September 3-6, 2016, San Diego, USA; Pluripotency: From basic science to therapeutic applications 22-24 March 2016 Kyoto, Japan

Scaffolds

Scaffolds are one of the three most important elements constituting the basic concept of regenerative medicine, and are included in the core technology of regenerative medicine. Every day thousands of surgical procedures are performed to replace or repair tissue that has been damaged through disease or trauma. The developing field of tissue engineering (TE) aims to regeneratedamaged tissuesby combining cells from the body with highly porous scaffold biomaterials, which act as templates for tissue regeneration, to guide the growth of new tissue. Scaffolds has a prominent role in tissue regeneration the designs, fabrication, 3D models, surface ligands and molecular architecture, nanoparticle-cell interactions and porous of thescaffoldsare been used in the field in attempts to regenerate different tissues and organs in the body. The world stem cell market was approximately 2.715 billion dollars in 2010, and with a growth rate of 16.8% annually, a market of 6.877 billion dollars will be formed in 2016. From 2017, the expected annual growth rate is 10.6%, which would expand the market to 11.38 billion dollars by 2021.

Related Conferences

InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; 5th InternationalConference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; 5th InternationalConference on Regenerative MedicineSeptember 12-14, 2016 Berlin, Germany; 2ndInternational Conference on Tissue preservationAugust 18-19, 2016 Portland, USA;Cell and Gene TherapyJanuary 25-27, 2016 Washington D.C., USA; ISSCRStem Cell Modelsof Neural Degeneration and Disease February 1-3, 2016 Dresden, Germany; Craniofacial Morphogenesis andTissue RegenerationMarch 12-18, 2016 California, USA; KeystoneStem Cells and Cancer(C1) March 6-10, Colorado, USA; KeystoneStem Cells and Regenerationin the Digestive Organs (X6) March 13 17 Colorado, USA

Tissue Regeneration Technologies

Guided tissue regeneration is defined as procedures attempting to regenerate lost periodontal structures through differential tissue responses. Guidedbone regenerationtypically refers to ridge augmentation or bone regenerative procedures it typically refers to regeneration of periodontal therapy. The recent advancements and innovations in biomedical and regenerative tissue engineering techniques include the novel approach of guided tissue regeneration and combination ofnanotechnologyand regenerative medicine.

Related Conferences

5th InternationalConferenceCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Bio-bankingAugust 18-19, 2016 Portland, USA;ISSCR Annual Meeting22-25 June, 2016 San Francisco, California, USA; KeystoneCardiac Development, Regeneration and Repair (Z2) April 3 7, 2016 Snowbird, Utah, USA;EMBLHematopoietic Stem Cells: From the Embryo to the Aging Organism, June 3-5, 2016 Heidelberg, Germany; ISSCRPluripotency: From basic science to therapeutic applications March 22-24, 2016 Kyoto, Japan

Regeneration and Therapeutics

Regenerative medicinecan be defined as a therapeutic intervention which replaces or regenerates human cells, tissues or organs, to restore or establish normal function and deploys small molecule drugs, biologics, medical devices and cell-based therapies. It deals with the different therapeutic uses like stem cells for tissue repair, tissue injury and healing process, cardiacstem cell therapyfor regeneration, functional regenerative recovery, effects of aging on tissuerepair/regeneration, corneal regeneration & degeneration. The global market is expected to reach $25.5 billion by 2011 and will further grow to $36.1 billion by 2016 at a CAGR of 7.2%. It is expected to reach $65 billion mark by 2024.

Related Conferences

5th InternationalConference on Tissue Engineering and Regenerative MedicineSeptember 12-14, 2016 Berlin, Germany; 5th InternationalConference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Cancer Immunologyand ImmunotherapyJuly 28-30, 2016 Melbourne, Australia; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; Tissue Niches andResident Stem Cells in Adult EpitheliaGordon Research Conference,Regulation of Tissue Homeostasisby Signalling in the Stem Cell Niche August 7-12, Hong Kong, China;10 Years of IPSCs, Cell Symposia, September 25-27, 2016 Berkeley, CA, USA; WorldStem Cells and Regenerative Medicine CongressMay 18-20, 2016 London, UK; Notch Signaling in Development,Regenerationand Disease Gordon Research Conference, July 31-August 5, 2016 Lewiston, ME, USA

Regenerative medicine

Regenerative medicine is a branch oftranslational researchin tissue engineering and molecular biology which deals with the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function. The latest developments involve advances in cell and gene therapy and stem cell research, molecular therapy, dental and craniofacial regeneration.Regenerative medicineshave the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process. These medicines are capable of restoring the functionality of cells and tissues. The global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020). Small molecules and biologics segment holds prominent market share in the overall regenerative medicine technology market and is anticipated to grow at a CAGR of 18.9% during the forecast period.

Related Conferences

InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; 5th InternationalConference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; 5th InternationalConference on Regenerative MedicineSeptember 12-14, 2016 Berlin, Germany; 2ndInternational Conference on Tissue preservationAugust 18-19, 2016 Portland, USA;Cell and Gene TherapyJanuary 25-27, 2016 Washington D.C., USA; ISSCRStem Cell Modelsof Neural Degeneration and Disease February 1-3, 2016 Dresden, Germany; Craniofacial Morphogenesis andTissue RegenerationMarch 12-18, 2016 California, USA; KeystoneStem Cells and Cancer(C1) March 6-10, Colorado, USA; KeystoneStem Cells and Regenerationin the Digestive Organs (X6) March 13 17 Colorado, USA

Applications of Tissue Engineering

The applications of tissue engineering and regenerative medicine are innumerable as they mark the replacement of medication andorgan replacement. The applications involve cell tracking andtissue imaging, cell therapy and regenerative medicine, organ harvesting, transport and transplant, the application of nanotechnology in tissue engineering and regenerative medicine and bio banking. Globally the research statistics are increasing at a vast scale and many universities and companies are conducting events on the subject regenerative medicine conference like tissue implants workshops, endodontics meetings, tissue biomarkers events, tissue repair meetings, regenerative medicine conferences, tissue engineering conference, regenerative medicine workshop, veterinary regenerative medicine, regenerative medicine symposiums, tissue regeneration conferences, regenerative medicine congress.

Related Conferences

5th InternationalConferenceCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Bio-bankingAugust 18-19, 2016 Portland, USA;ISSCR Annual Meeting22-25 June, 2016 San Francisco, California, USA; KeystoneCardiac Development, Regeneration and Repair (Z2) April 3 7, 2016 Snowbird, Utah, USA;EMBLHematopoietic Stem Cells: From the Embryo to the Aging Organism, June 3-5, 2016 Heidelberg, Germany; ISSCRPluripotency: From basic science to therapeutic applications March 22-24, 2016 Kyoto, Japan

Regenerative Medicine Market

There are strong pricing pressures from public healthcare payers globally as Governments try to reduce budget deficits. Regenerative medicine could potentially save public health bodies money by reducing the need for long-term care and reducing associated disorders, with potential benefits for the world economy as a whole.The global market fortissue engineeringand regeneration products reached $55.9 billion in 2010, is expected to reach $59.8 billion by 2011, and will further grow to $89.7 billion by 2016 at a compounded annual growth rate (CAGR) of 8.4%. It grows to $135 billion to 2024. The contribution of the European region was 43.3% of the market in 2010, a value of $24.2 billion. Themarketis expected to reach $25.5 billion by 2011 and will further grow to $36.1 billion by 2016 at a CAGR of 7.2%. It grows to $65 billion to 2024.

Related Conferences

5th InternationalConference on Tissue Engineeringand Regenerative MedicineSeptember 12-14, 2016 Berlin, Germany; 3rd 2nd InternationalConference on Tissue preservationand Bio-bankingAugust 18-19, 2016 Portland, USA; 5th InternationalConference on Cell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; 10thWorld Biomaterials CongressMay 17-22, 2016 Quebec, Canada; 2016TERMIS-EU ConferenceJune 28- July1, 2016 Uppsala, Sweden; 2016TERMIS-AP ConferenceTamsui Town of New Taipei City May 23-28, 2016; 2016TERMIS-AM ConferenceSeptember 3-6, 2016, San Diego, USA;Pluripotency: From basic science to therapeutic applications22-24 March 2016 Kyoto, Japan

Regenerative Medicine Europe

Leading EU nations with strong biotech sectors such as the UK and Germany are investing heavily in regenerative medicine, seeking competitive advantage in this emerging sector. The commercial regenerative medicine sector faces governance challenges that include a lack of proven business models, an immature science base and ethical controversy surrounding hESC research. The recent global downturn has exacerbated these difficulties: private finance has all but disappeared; leading companies are close to bankruptcy, and start-ups are struggling to raise funds. In the UK the government has responded by announcing 21.5M funding for the regenerative medicine industry and partners. But the present crisis extends considerably beyond regenerative medicine alone, affecting much of the European biotech sector. A 2009 European Commission (EC) report showed the extent to which the global recession has impacted on access to VC finance in Europe: 75% of biopharma companies in Europe need capital within the next two years if they are to continue their current range of activities.

Related Conferences

InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; 5th InternationalConference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; 5th InternationalConference on Regenerative MedicineSeptember 12-14, 2016 Berlin, Germany; 2ndInternational Conference on Tissue preservationAugust 18-19, 2016 Portland, USA;Cell and Gene TherapyJanuary 25-27, 2016 Washington D.C., USA; ISSCRStem Cell Modelsof Neural Degeneration and Disease February 1-3, 2016 Dresden, Germany; Craniofacial Morphogenesis andTissue RegenerationMarch 12-18, 2016 California, USA; KeystoneStem Cells and Cancer(C1) March 6-10, Colorado, USA; KeystoneStem Cells and Regenerationin the Digestive Organs (X6) March 13 17 Colorado, USA

Embryonic Stem Cell

Embryonic stem cells are pluripotent, meaning they are able to grow (i.e. differentiate) into all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. In other words, they can develop into each of the more than 200 cell types of the adult body as long as they are specified to do so. Embryonic stem cells are distinguished by two distinctive properties: their pluripotency, and their ability to replicate indefinitely. ES cells are pluripotent, that is, they are able to differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm, and mesoderm. These include each of the more than 220 cell types in the adult body. Pluripotency distinguishes embryonic stem cells from adult stem cells found in adults; while embryonic stem cells can generate all cell types in the body, adult stem cells are multipotent and can produce only a limited number of cell types. Additionally, under defined conditions, embryonic stem cells are capable of propagating themselves indefinitely. This allows embryonic stem cells to be employed as useful tools for both research and regenerative medicine, because they can produce limitless numbers of themselves for continued research or clinical use.

Related Conferences

5th InternationalConference on Tissue Engineering and Regenerative MedicineSeptember 12-14, 2016 Berlin, Germany; 5th InternationalConference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Cancer Immunologyand ImmunotherapyJuly 28-30, 2016 Melbourne, Australia; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; Tissue Niches andResident Stem Cells in Adult EpitheliaGordon Research Conference,Regulation of Tissue Homeostasisby Signalling in the Stem Cell Niche August 7-12, Hong Kong, China;10 Years of IPSCs, Cell Symposia, September 25-27, 2016 Berkeley, CA, USA; WorldStem Cells and Regenerative Medicine CongressMay 18-20, 2016 London, UK; Notch Signaling in Development,Regenerationand Disease Gordon Research Conference, July 31-August 5, 2016 Lewiston, ME, USA

Stem Cell Transplant

Stem cell transplantation is a procedure that is most often recommended as a treatment option for people with leukemia, multiple myeloma, and some types of lymphoma. It may also be used to treat some genetic diseases that involve the blood. During a stem cell transplant diseased bone marrow (the spongy, fatty tissue found inside larger bones) is destroyed with chemotherapy and/or radiation therapy and then replaced with highly specialized stem cells that develop into healthy bone marrow. Although this procedure used to be referred to as a bone marrow transplant, today it is more commonly called a stem cell transplant because it is stem cells in the blood that are typically being transplanted, not the actual bone marrow tissue.

Related Conferences

5th InternationalConference Cell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 5th InternationalConference on Tissue EngineeringSeptember 12-14, 2016 Berlin, Germany; 2nd InternationalConference on Tissue preservationAugust 18-19, 2016 Portland, USA; Molecular and Cellular Basis ofGrowth and Regeneration(A3) January 10 14, 2016 Colorado, USA;Cell and Gene TherapyJanuary 25-27, 2016 Washington D.C., USA; ISSCRStem Cell Modelsof Neural Degeneration and Disease March 13 17, 2016 Dresden, Germany; Craniofacial Morphogenesis andTissue RegenerationMarch 12-18, 2016 California, USA;World Stem Cells CongressMay 18-20, 2016 London, UK

Market Analysis Report:

Tissue engineering is an interdisciplinary field that applies the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function or a whole organ. Regenerative medicine is not one discipline. It can be defined as a therapeutic intervention which replaces or regenerates human cells, tissues or organs, to restore or establish normal function and deploys small molecule drugs, biologics, medical devices and cell-based therapies

Currently it has emerged as a rapidly diversifying field with the potential to address the worldwide organ shortage issue and comprises of tissue regeneration and organ replacement. Regenerative medicine could potentially save public health bodies money by reducing the need for long-term care and reducing associated disorders, with potential benefits for the world economy as a whole.The global tissue engineering and regeneration market reached $17 billion in 2013. This market is expected to grow to nearly $20.8 billion in 2014 and $56.9 billion in 2019, a compound annual growth rate (CAGR) of 22.3%. On the basis of geography, Europe holds the second place in the global market in the field of regenerative medicine & tissue engineering. In Europe countries like UK, France and Germany are possessing good market shares in the field of regenerative medicine and tissue engineering. Spain and Italy are the emerging market trends for tissue engineering in Europe.

Tissue engineering is "an interdisciplinary field that applies the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function or a whole organ. Currently it has emerged as a rapidly diversifying field with the potential to address the worldwide organ shortage issue and comprises of tissue regeneration and organ replacement. A novel set of tissue replacement parts and implementation strategies had shown a great revolution in this field. Cells placed on or within the tissue constructs is the most common methodology in tissue engineering.

Regenerative medicine is not one discipline. It can be defined as a therapeutic intervention which replaces or regenerates human cells, tissues or organs, to restore or establish normal function and deploys small molecule drugs, biologics, medical devices and cell-based therapies

This field continues to evolve. In addition to medical applications, non-therapeutic applications include using tissues as biosensors to detect biological or chemical threat agents, and tissue chips that can be used to test the toxicity of an experimental medication. Tissue Engineering and Regenerative Medicine is the major field in Medicine, which is still under research and the advancements are maximizing day to day.

Regenerative Medicine-2015 is an engrossed a vicinity of cognizant discussions on novel subjects like Tissue Regeneration, Materials & Designs for Tissue Engineering, Stem CellTools to Battle Cancer, Bioreactors in Tissue Engineering, Regeneration & Therapeutics, Cord Blood & Regenerative Medicine and Clinical Medicine, to mention a few. The three days event implants a firm relation of upcoming strategies in the field of Tissue Science & Regenerative Medicine with the scientific community. The conceptual and applicable knowledge shared, will also foster organizational collaborations to nurture scientific accelerations.We bring together business, creative, and technology leaders from the tissue engineering, marketing, and research industry for the most current and relevant.

Berlin is one of the largest and most diverse science regions in Europe. Roughly 200,000 people from around the world teach, research, work and study here. Approximately 17 percent of all students come from abroad, most of them from China, Russia and the USA. Many cooperative programs link Berlins institutes of higher education with partner institutes around the world. Berlin is a city of science at the heart of Europe a city whose history of scientific excellence stems from its many important research institutions and its long track record of scientific breakthroughs. Berlin has numerous modern Technology Centers. Their science-oriented infrastructure makes them attractive locations for young, technology-oriented companies.

Germany places great emphasis on globally networked research cooperation. Many organizations support international researchers and academics: Today more than 32,000 are being supported with scholarships. Besides this, research funding in Germany has the goal of financing the development of new ideas and technologies. The range covers everything from basic research in natural sciences, new technologies to structural research funding at institutions of higher education. On the basis of geography, the regenerative medicine bone and joint market Europe hold the second place in the global market in the field of regenerative medicine & tissue engineering. The market growth is expected to reach $65 billion by 2024 in Europe. In Europe countries like UK, France, and Germany are possessing good market share in the field of regenerative medicine and tissue engineering. Spain and Italy are the emerging market trends for tissue engineering in Europe. As per the scope and emerging market for tissue engineering and regenerative medicine Berlin has been selected as Venue for the 5th International Conference on Tissue Science and Regenerative Medicine.

Meet Your Target MarketWith members from around the world focused on learning about Advertising and marketing, this is the single best opportunity to reach the largest assemblage of participants from the tissue engineering and regenerative medicine community. The meeting engrossed a vicinity of cognizant discussions on novel subjects like Tissue Regeneration, Materials & Designs for Tissue Engineering, Stem CellTools to Battle Cancer, Bioreactors in Tissue Engineering, Regeneration & Therapeutics, Cord Blood & Regenerative Medicine and Clinical Medicine, to mention a few. The three days event implants a firm relation of upcoming strategies in the field of Tissue Engineering & Regenerative Medicine with the scientific community. The conceptual and applicable knowledge shared, will also foster organizational collaborations to nurture scientific accelerations.Conduct demonstrations, distribute information, meet with current and potential customers, make a splash with a new product line, and receive name recognition.

International Stem Cell Forum (ISCF)

International Society for Stem Cell Research (ISSCR)

UK Medical Research Council (MRC)

Australian Stem Cell Center

Canadian Institutes of Health Research (CIHR)

Euro Stem Cell (ACR)

Center for Stem Cell Biology

Stem Cell Research Singapore

UK National Stem Cell Network

Spain Mobile Marketing Association

European Marketing Confederation (EMC)

European Letterbox Marketing Association(ELMA)

European Sales & Marketing Association (ESMA)

The Incentive Marketing Association (IMA Europe)

European Marketing Academy

Figure 1: Statistical Analysis of Societies and Associations

Source: Reference7

Presidents or Vice Presidents/ Directors of Associations and Societies, CEOs of the companies associated with regenerative medicine and tissue engineering Consumer Products. Retailers, Marketing, Advertising and Promotion Agency Executives, Solution Providers (digital and mobile technology, P-O-P design, retail design, and retail execution), Professors and Students from Academia in the study of Marketing and Advertising filed.

Industry 40%

Academia 50%

Others 10%

Read the original post:
Regenerative Medicine Conferences | Europe | CPD Events ...

Posted in Uncategorized | Comments Off on Regenerative Medicine Conferences | Europe | CPD Events …